|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Synthetic Biology and the Environmentalmost 6 years ago
Measuring Pharma’s Wider Mandatealmost 6 years ago
Patients as the North Staralmost 6 years ago
Going Public During Lockdown: IPO Insights from Five Biotechnology CFOsalmost 6 years ago
A Rare-Disease Must? Building Long-Term Relationshipsalmost 6 years ago
Making Remote Work a Success Beyond COVIDalmost 6 years ago
CRISPR for Diversity, and Humanity’s, Sakealmost 6 years ago
Expediting the Cancer Treatment Pathalmost 6 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesalmost 6 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
3
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
4
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
5